Why monitor the neonatal brain-that is the important question.
Vanhatalo. Sampsa S; Stevenson. Nathan J NJ; Pressler. Ronit M RM; Abend. Nicholas S NS; Auvin. Stéphane S; Brigo. Francesco F; Cilio. M Roberta MR; Hahn. Cecil D CD; Hartmann. Hans H; Hellström-Westas. Lena L; Inder. Terrie E TE; Moshé. Solomon L SL; Nunes. Magda L ML; Shellhaas. Renée A RA; Vinayan. Kollencheri P KP; de Vries. Linda S LS; Wilmshurst. Jo M JM; Yozawitz. Elissa E; Boylan. Geraldine B GB
Key Findings
- The NEST trial showed no outcome advantage of aEEG monitoring over clinical seizure identification in neonates.
- The trial did not prove that brain monitoring changes seizure treatment decisions.
- There is currently no evidence that routine neonatal brain monitoring improves health outcomes.
Practical Outcomes
- For biohackers and self‑experimenters, this research offers no actionable protocol or dosage guidance; it simply indicates that neonatal brain monitoring isn’t proven to help, so it isn’t relevant to personal health optimization strategies.
Summary
The study examined if using a special brain‑wave monitor (aEEG) on newborns improves outcomes compared to just watching for seizures clinically, and it found no benefit.
Abstract
A key goal of neonatal neurocritical care is improved outcomes, and brain monitoring plays an essential role. The recent NEST trial reported no outcome benefits using aEEG monitoring compared to clinical seizure identification among neonates treated for seizures. However, the study failed to prove the effects of monitoring on seizure treatment in the first place.
Study Information
pubmed
2022
2022-04-01T00:00:00.000Z
10.1038/s41390-022-02040-9
14
12